title: TARC and IL-5 expression correlates with tissue eosinophilia in peripheral T-cell lymphomas.
abstract: The current study attempts to characterize the eosinophilia associated with T-cell lymphomas and to investigate its possible relationship with the secretion of eosinophil-stimulating factors by lymphoma cells and/or intra-tumoral surrounding cells. Paraffin-embedded specimens from 50 patients diagnosed with peripheral T-cell lymphomas, either unspecified (PTCL-U, n=30) or angioimmunoblastic (AITL, n=20) were morphologically assessed for intra-tumoral eosinophilia and analyzed by immunohistochemistry using specific antibodies directed against TARC, IL-5, RANTES, and eotaxin. The AITL and PTCL-U cases contained a mean of 147+/-41 and 102+/-37 eosinophils per 10 high power fields, respectively. Thirty-two of 47 cases (68%) showed IL-5-positive lymphoma cells while 15/50 (30%) tumors showed variable staining for TARC in scattered non-lymphoid cells with dendritic morphology. TARC and IL-5-positive cases possessed significantly more eosinophils. Our data indicate that IL-5 and TARC expression highly correlate with eosinophilia in T-cell lymphomas, suggesting that these chemokines are involved in the recruitment of eosinophils into the tumors.
authors.affiliation: Department of Pathology, CHU of Liège, University of Liège, Liège, Belgium. C.thielen@ulg.ac.be
authors.forename: Caroline
authors.initials: C
authors.lastname: Thielen
authors.forename: Vincent
authors.initials: V
authors.lastname: Radermacher
authors.forename: Mounir
authors.initials: M
authors.lastname: Trimeche
authors.forename: Florence
authors.initials: F
authors.lastname: Roufosse
authors.forename: Michel
authors.initials: M
authors.lastname: Goldman
authors.forename: Jacques
authors.initials: J
authors.lastname: Boniver
authors.forename: Laurence
authors.initials: L
authors.lastname: de Leval
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D054413:Chemokine CCL11 / Q000378:metabolism; D054414:Chemokine CCL17 / Q000378:metabolism*; D018946:Chemokine CCL5 / Q000378:metabolism; D004802:Eosinophilia / Q000378:metabolism* / Q000473:pathology; D004804:Eosinophils / Q000473:pathology; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000378:metabolism / Q000473:pathology; D007124:Immunoenzyme Techniques; D015848:Interleukin-5 / Q000378:metabolism*; D016411:Lymphoma, T-Cell, Peripheral / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: C515456:CCL11 protein, human; C106230:CCL17 protein, human; D054413:Chemokine CCL11; D054414:Chemokine CCL17; D018946:Chemokine CCL5; C508599:IL5 protein, human; D015848:Interleukin-5